1. Home
  2. HBB vs STTK Comparison

HBB vs STTK Comparison

Compare HBB & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Beach Brands Holding Company

HBB

Hamilton Beach Brands Holding Company

HOLD

Current Price

$17.99

Market Cap

236.4M

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.13

Market Cap

275.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBB
STTK
Founded
1904
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
236.4M
275.9M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
HBB
STTK
Price
$17.99
$6.13
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$7.60
AVG Volume (30 Days)
22.6K
658.7K
Earning Date
04-29-2026
03-05-2026
Dividend Yield
2.92%
N/A
EPS Growth
N/A
53.02
EPS
1.95
N/A
Revenue
$606,852,000.00
$1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.72
$0.69
52 Week High
$20.75
$6.31

Technical Indicators

Market Signals
Indicator
HBB
STTK
Relative Strength Index (RSI) 53.44 71.32
Support Level $17.95 $1.85
Resistance Level $20.33 N/A
Average True Range (ATR) 0.89 0.43
MACD 0.03 0.04
Stochastic Oscillator 69.12 90.87

Price Performance

Historical Comparison
HBB
STTK

About HBB Hamilton Beach Brands Holding Company

Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: